Theodora Bejan-Angoulvant
  • E-mail :[email]
  • Phone : +332 34 37 96 65
  • Location : Tours, France
Last update 2020-04-30 12:05:46.139

Theodora Bejan-Angoulvant Prof. Theodora Bejan-Angoulvant, M.D., Ph.D., clinical pharmacology & research methodology

Course and current status


Medical school at UFR Cochin-Port Royal, Paris 5, René Descartes University.

Clinical training at University Hospital of Lyon, France and Claude Bernard University Lyon 1, Lyon, France. MD obtained in 2003.

Research training, 2005-2011 at UMR CNRS 5558 LBBE, EMET Group (Prof François Gueyffier), Lyon, France ( PhD obtained in 2010.

Research and PhD fellowship "Coeur et Santé" (modelling of blood pressure lowering drugs) from the French Society of Hypertension, 2006.

Research grant, MIAMIGO project (immuno monotoring of monoclonal antibodies), Grand Ouest inter-region, France, 2013.

Current position

Professor of clinical pharmacology (Medical Pharmacology department) at Tours University Hospital, Hôpital Bretonneau, and Tours University, Tours, France.

Senior researcher at EA 4245 « Transplantation Immunity Inflammation » member of the MABimprove research group.

Member of Faculty of Medecine Council, Ethics commission and Relations with the University (

Member of Hospital Medical Commission, University Hospital of Tours (

Scientific summary


My research focus on clinical efficacy and adverse effects of drugs, mainly monoclonal antibodies but also all drugs used in cardiovascular diseases. I am also interested in various aspects of the methodology of clinical trials

I am collaborating with the MABImprove research group ( specialized in the development and evaluation of monoclonal antibodies for the treatment of numerous diseases including cardiovascular diseases.

I coordinate the Research Grant for Young Investigators from the University Hospital of Tours, since 2018.

Editorial activities

Member of the scientific board of Therapie, journal of the French Society of Pharmacology and Therapeutics

Medical and scientific societies 

Member of the European Association for Clinical Pharmacology and Therapeutics (EACPT:

Elected member of the board of French Society of Hypertension (SFHTA:

Member of the French Society of Pharmacology and Therapeutics (SFPT:

French Medicine Agency

Member of the Therapeutics and Cardiovascular risk committee of the Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM:

Image d’exemple